Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H29N5O3S |
Molecular Weight | 491.605 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=NC2=C(C=C(C)N=C2C)N1C3=CC=C(CCNC(=O)NS(=O)(=O)C4=CC=C(C)C=C4)C=C3
InChI
InChIKey=HZVLFTCYCLXTGV-UHFFFAOYSA-N
InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32)
Molecular Formula | C26H29N5O3S |
Molecular Weight | 491.605 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
GALLIPRANT® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist; a non-cyclooxygenase (COX) inhibiting, non-steroidal antiinflammatory drug (NSAID) in the piprant class. Grapiprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. It is approved for veterinary use, but it is in phase II development in Japan for the treatment of chronic inflammatory pain, including osteoarthritis and rheumatoid arthritis. Grapiprant shows similar in vitro binding affinity (Ki) for the rat and dog EP4 receptor, 20 and 24 nM, respectively.
Originator
Sources: http://adisinsight.springer.com/drugs/800029996
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
13.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GALLIPRANT Approved UseGALLIPRANT (grapiprant tablets) is indicated for the control of pain and inflammation
associated with osteoarthritis in dogs Launch Date2016 |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
Dogs: The dose of GALLIPRANT (grapiprant tablets) is 0.9 mg/lb (2 mg/kg) once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27597397
The EP4 receptor membrane prepared from the EP4-HEK293
cells demonstrated a single affinity site for PGE2 binding with
Kd value of 2.3 nM. Grapiprant displaced [3H]-
PGE2 (1 nM) binding to dog recombinant EP4 receptor in a
concentration-dependent manner with an IC50 value of
35 +/- 3.9 nM and with a Ki value of 24 +/- 2.7 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:11:13 GMT 2023
by
admin
on
Sat Dec 16 17:11:13 GMT 2023
|
Record UNII |
J9F5ZPH7NB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.1084
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12836
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
C124131
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
ZZ-127
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
J9F5ZPH7NB
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
1862951
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
11677589
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
9763
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
Grapiprant
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
J9F5ZPH7NB
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
100000183293
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
m11902
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
DTXSID60194419
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
415903-37-6
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL3039498
Created by
admin on Sat Dec 16 17:11:13 GMT 2023 , Edited by admin on Sat Dec 16 17:11:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
BINDING
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Cmax | PHARMACOKINETIC |
|
|
|||